Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02298829 · ClinicalTrials.gov registry record
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
A clinical trial, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- 184
- Enrollment target
NCT02298829: Completed study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT02298829 is a clinical trial that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 184 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02298829 has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- 184 participants
- Enrollment target
Study Summary
This a Phase 4 non-treatment, long-term follow-up study of subjects who received AA4500 in a 12-month double blind placebo-controlled study (AUX CC 803 or AUX-CC-804) or in a 9-month open label study (AUX-CC-802 or AUX-CC-806) sponsored by Auxilium Pharmaceuticals, Inc. After participation in one of the aforementioned studies, subjects will be followed yearly for up to 4 consecutive long-term follow-up visits with at least 6 months between consecutive visits
Interventions
- DRUG Subjects Previously Treated with AA4500
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2014-11 |
| Est. Completion | 2018-04-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02298829
The ClinicalTrials.gov registry entry for NCT02298829 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Subjects Previously Treated with AA4500 is the first listed.
NCT02298829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02298829 about?
NCT02298829 is a clinical study titled "Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease". This a Phase 4 non-treatment, long-term follow-up study of subjects who received AA4500 in a 12-month double blind placebo-controlled study (AUX CC 803 or AUX-CC-804) or in a 9-month open label study (AUX-CC-802 or AUX-CC-806) sponsored by Auxilium Pharmaceuticals, Inc. After participation in one of...
What is the current status of trial NCT02298829?
This trial is currently completed. The enrollment target is 184 participants. The study started on 2014-11. Estimated completion is 2018-04-09.
What interventions are being tested in trial NCT02298829?
The interventions under investigation include: Subjects Previously Treated with AA4500 (DRUG).
Who is sponsoring clinical trial NCT02298829?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.